The Florida-based startup Ambrosia, founded in 2016 by Stanford Medical School graduate Jesse Karmazin, offer new, young plasma to help combat against the aging process for patients 30 years and older. They have six locations around the country (Phoenix, AZ, Los Angeles, CA, San Francisco, CA, Tampa, FL, Omaha, NE and Houston, TX) and the price starts at $8,000 for one liter. The plasma is from carefully screened donors between 16 and 25 years old.
Oh, and there’s a waiting list.
“Plasma is the liquid part of the blood that contains proteins crucial to overall health. Typically, only people who have liver failure, severe burns, or severe infections receive plasma transfusions, but the case is not the same for a controversial startup that’s offering the service as an anti-aging therapy.”1
According to Ambrosia, they conducted a clinical trial back in 2017 to look at the effects of new plasma on the old and their results- which they have yet to release to the public- were positive. However, currently, no scientific evidence exists to prove that plasma infusions work as an anti-aging therapy.
That said, the FDA does approve blood transfusions so “it’s likely that the company is using it ‘off-label,’ meaning that an FDA-approved drug or procedure is being used for unapproved use.”2
For more info on the company or to join the waiting list, click here.